For the year ending 2025-12-31, XAGE had $549,601 increase in cash & cash equivalents over the period. -$3,343,491 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss from continuing operations | -6,905,282 |
| Stock-based compensation | 692,790 |
| Depreciation and amortization of intangible assets | 78,675 |
| Amortization of right of use assets | 136,379 |
| Change in fair value of earnout liabilities | -149,584 |
| Inventory write-down | 60,963 |
| Accounts receivable and other current assets | -44,151 |
| Inventory | -370,853 |
| Prepaid expenses | -537,685 |
| Income taxes receivable | -301,838 |
| Accounts payable | 126,858 |
| Accrued expenses and other liabilities | 1,515,945 |
| Lease liability | -140,537 |
| Net cash used in operating activities | -3,329,266 |
| Cash paid for elevai acquisition transaction costs | 150,000 |
| Purchases of property and equipment | 14,225 |
| Net cash used in investing activities | -164,225 |
| Proceeds from issuance of common stock, net of costs | 3,483,790 |
| Proceeds from exercise of common stock warrants | 1,000,000 |
| Repayment of loans | 440,698 |
| Net cash provided by financing activities | 4,043,092 |
| Net increase (decrease) in cash and cash equivalents | 549,601 |
| Cash and cash equivalents - beginning of period | 157,139 |
| Cash and cash equivalents - end of period | 706,740 |
Longevity Health Holdings, Inc. (XAGE)
Longevity Health Holdings, Inc. (XAGE)